Literature DB >> 11153807

An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.

C B Nemeroff1.   

Abstract

Bipolar disorder is a recurrent and relapsing mood disorder characterized by cycles of depression and mania. This article addresses the treatment of patients with bipolar mania, which remains one of the most difficult challenges facing clinicians. Patients require safe and effective therapeutic approaches for acute episodes of mania and depression, as well as chronic prophylaxis against future episodes. Monotherapeutic approaches are rarely effective, and combination approaches are associated with an increased risk of adverse events. Lithium is the only agent currently approved for the treatment of both acute episodes of mania and maintenance therapy; however, it is associated with a relatively poor response rate, high relapse rate, and less-than-optimal side effect profile. Other recent approaches have included several anticonvulsant agents, as well as conventional and atypical antipsychotic agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11153807

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Psychiatric Uses of Newer Anticonvulsants.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-04

Review 2.  Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder.

Authors:  Toni M Dando; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Adjunctive topiramate treatment in refractory obese bipolar patients: a descriptive open label study.

Authors:  A Gabriel
Journal:  Eat Weight Disord       Date:  2007-03       Impact factor: 4.652

4.  Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission.

Authors:  Giuseppe Tringali; Jean Michel Aubry; Katiuscia Moscianese; Claudia Zamori; Mauro Vairano; Paolo Preziosi; Pierluigi Navarra; Giacomo Pozzoli
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

5.  Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects.

Authors:  Jagdev Sidhu; Sarah Job; Jonathan Bullman; Emma Francis; Richard Abbott; John Ascher; Jochen G W Theis
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

Review 6.  Bipolar spectrum disorders. New perspectives.

Authors:  Andre Piver; Lakshmi N Yatham; Raymond W Lam
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.